Navigation Links
Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Date:9/17/2007

ANN ARBOR, Mich., Sept. 17 /PRNewswire/ -- Terumo Heart, Inc. announced today that it had a successful European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the DuraHeart(TM) Left Ventricular Assist System (LVAS) was presented by Dr. Aly El-Banayosy from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, followed by the presentation "The Emerging New Era of Mechanical Circulatory Support," by Dr. Eric Rose of Columbia University Medical Center in New York.

The symposium highlighted the DuraHeart device, as well as the BioValsalva Aortic Valved Conduit developed by Vascutek Ltd, a Terumo Company.

A summary of DuraHeart LVAS clinical results to-date (as of September 15, 2007):

* Patients enrolled = 33

* Median age (years) = 57 (29-73)

* Mean support duration (days) = 231194 (range: 17-803)

* Cumulative support duration = 7610 days (> 20 years)

* 7 patients (21%) supported > 1 year, and one supported > 2 years.

* 12 patients (36%) remain on support with a mean duration > 1 year (375

196 days)

* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (<65

yrs), 90% (<60 yrs) and 100% (<50)

Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said; "We have had a number of significant milestones this year, most importantly receiving the CE Mark and a successful commercial launch in Europe."

The interest from surgeons at the EACTS has been extremely good. Dr. Nojiri commented, "We have been very pleased with the amount of interest from surgeons, both at this meeting and since receipt of the CE Mark. We are focusing significant resources on commercial activities in Europe and are looking forward to a U.S. clinical trial later this year."

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only approved implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. DuraHeart is not available in the United States.

Vascutek Deutschland GmbH, a Terumo Company, distributes DuraHeart through its Terumo Heart Division based in Hamburg, Germany. Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading

developer, manufacturer and global marketer of a wide array of medical products.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) ... facility among higher education institutions in Hong Kong to support teaching, learning and research. ... range and quantity of facilities in Hong Kong. , With an area of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Joseph Health held the much anticipated Regional Primary Care Spring Symposium on April ... in the local medical community, offering physicians and healthcare providers an opportunity to ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Detroit reveals good news for older shoulder replacement patients; post-operative recovery just might ... from two groups of patients presenting with osteoarthritis following surgery: 262 patients under ...
Breaking Medicine News(10 mins):